Phase 3 Leukaemia Trial, Recruiting NCT05991908 Sponsor: Shanghai Jiao Tong University School of Medicine Condition: Leukaemia
Back to Leukaemia

Phase 3 Leukaemia Trial, Recruiting

NCT05991908
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with acute myeloid leukemia (a type of blood cancer, but not the specific subtype called acute promyelocytic leukemia) and whose disease is currently in first complete remission (meaning treatment has worked and signs of cancer are no longer detectable)
  • People who have a bone marrow disorder called myelodysplasia syndrome, where between 5% and 20% of their bone marrow cells are abnormal blast cells at the time of transplant
  • People who have a suitable stem cell donor available — either a brother or sister whose tissue type closely matches, an unrelated donor with a 9 out of 10 or 10 out of 10 tissue match, or a related donor who is a half-match (called a haploidentical donor)
  • People who have given their informed consent to participate in the trial

Who may not be able to join:

  • People with acute myeloid leukemia that has spread to the central nervous system (brain and spinal cord) or to other parts of the body outside the bone marrow
  • People who currently have an active infection, whether caused by a virus, bacteria, or fungus
  • People who have hepatitis B virus levels above a certain threshold in their blood (confirm with trial site for exact measurement)
  • People who have abnormal liver function, kidney function, breathing problems, or heart problems
  • People who have a mental health condition that is not currently under control
  • People who have HIV

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Chun Wang, Go Broad Health Center, Zhaxin Hospital

Phone: 13386259777

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Shanghai Jiao Tong University School of Medicine
Registry
ClinicalTrials.gov
Start date
19 October 2023
Est. completion
30 October 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

disease-free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov